Here are six key points:
1. The financing consists of €15 million, or $16.7 million, in convertible bonds and €5 million, or $5.5 million, in equity. The sole investor in the convertible bonds is Athyrium Capital Management.
2. Additionally, in the equity private placement, Medicrea will issue 1.02 million in common shares.
3. Medicrea will use the funds to further commercialize its UNiD Patient-Specific Rods in the U.S. market.
4. It also plans to begin commercializing the technology in new international markets.
5. Mr. Kienzle, who will also join Medicrea’s board of directors, was a founding member of Globus Medical.
6. He served as Globus Medical’s executive vice president of global sales and marketing.
More articles on devices:
Flower Orthopedics launches the MTP Fusion Plate Portfolio: 3 things to know
NeuroMetrix’s Quell Health Cloud gathered 1M+ hours of Quell therapy, health data: 5 key pointsNeuroMetrix’s Quell Health Cloud gathered 1M+ hours of Quell therapy, health data: 5 key points
Corin Group, FX Solutions sign distribution agreement for US market: 4 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
